Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

New therapy mounts double-barreled attack on leukemia, report UF researchers

A new therapy mounts a double-barreled attack on leukemia, targeting not just the cancer cells but also the environment in which those cells live and grow, University of Florida researchers report.

4 Jun 2010

Testosterone deficiency can lead to multiple disorders

Almost a quarter of men treated for cancer in their childhood suffer from a deficiency of the male sex hormone testosterone.

3 Jun 2010

ENMD-2076 demonstrates antitumor activity against murine xenograft models of CRC: Study

EntreMed, Inc., today announced the publication of preclinical results for its clinical-stage Aurora A/angiogenic kinase inhibitor, ENMD-2076, in human colorectal cancer xenograft models. The results of the study, conducted by EntreMed collaborators at the University of Colorado School of Medicine, were published in the June 1, 2010 issue of Clinical Cancer Research (Vol. 16, Issue 11).

2 Jun 2010

Asuragen obtains license to integrate BRAF V600E mutation sequence into its molecular diagnostic products

Asuragen, Inc., a leader in molecular diagnostics and RNA-based pharmacogenomics services, announced today that it has obtained a non-exclusive license to incorporate the BRAF V600E mutation sequence into Asuragen's molecular diagnostic products. The license was obtained from Johns Hopkins University and includes the use of the BRAF V600E mutation as a component of diagnostic test kits and for use in Asuragen's CLIA laboratory for clinical research and patient testing.

2 Jun 2010

New research project to discover origin of myelodysplasia

The University of Navarra, together with the University of Oxford and three other European centres, are taking part in a project to discover the origin of myelodysplasia, an ailment with a predisposition to develop into leukaemia. In the work, patients from 19 hospitals in the north of Spain - including the University Hospital of Navarra - were analysed, as well as from England, Italy, Sweden and Germany.

2 Jun 2010

Results from AMRI's on-going Phase I clinical study of ALB 109564(a) published online

AMRI announced today that on-going results from its Phase I clinical study on its novel tubulin inhibitor, ALB 109564(a), were published on the website of the American Society of Clinical Oncology (abstract.asco.org/alb). These results indicate that ALB 109564(a) is well tolerated at the doses tested and shows preliminary evidence of clinical activity in disease types not typically treated with approved vinca alkaloids.

2 Jun 2010

Research team confirms gene mutation associated with serious forms of leukaemia

1 Jun 2010

EpiCept provides update on post-approval commitments requested by EMA for Ceplene

EpiCept Corporation today provided an update on the post-approval commitments requested by the European Medicines Agency as part of its marketing authorization for Ceplene (histamine dihydrochloride). Ceplene is approved in the EU for remission maintenance and prevention of relapse in adults with Acute Myeloid Leukemia in first complete remission.

1 Jun 2010

Scientists identify new susceptibility genes in genome-wide association study of nasopharyngeal carcinoma

Scientists from Singapore, China and USA have identified three new susceptibility genes in a genome-wide association study of nasopharyngeal carcinoma (NPC). The study, led by the Genome Institute of Singapore (GIS), a biomedical research institute of the Agency for Science, Technology and Research (A*STAR), and the Sun Yat-Sen University Cancer Centre, identified genetic risk factors of NPC that advance the understanding of the important role played by host genetic variation in influencing the susceptibility to this cancer.

31 May 2010

Adenosine plays major role in parlaying effects of acupuncture

Scientists have taken another important step toward understanding just how sticking needles into the body can ease pain.

31 May 2010

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced initiation of a Phase 2 proof-of-concept clinical trial to evaluate the preliminary efficacy and safety of its oncology drug candidate bafetinib in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL).

29 May 2010

Advocates urge Congress to reauthorize C.W. Bill Young Cell Transplantation Program and NCBI

More than 60 adult donors, transplant recipients, family members and medical professionals from 25 states met with lawmakers and staff on Capitol Hill today to urge Congress for increased federal funding to grow and diversify the national registry of adult donors and publicly available cord blood units as part of the C.W. Bill Young Transplantation Program and the National Cord Blood Inventory.

28 May 2010

CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that its drug candidate bafetinib (formerly known as INNO-406) demonstrated statistically significant inhibition of glioblastoma multiforme cell lines in a preclinical trial. Glioblastoma multiforme is the most common and aggressive primary adult brain tumor.

28 May 2010

OHSU partners with UO, Harvard to expedite research into compounds that may prevent Fanconi anemia

Oregon Health & Science University is partnering with the University of Oregon and Harvard Medical School to expedite basic science research into new and existing drugs and compounds that may prevent the complications associated with Fanconi anemia, an inherited condition that can lead to bone marrow failure and cancer.

28 May 2010

Genentech uses Complete Genomics' sequencing service to compare primary lung tumor, adjacent normal tissue

Complete Genomics Inc., a third-generation human genome sequencing company, today announced that Genentech Inc., a wholly owned member of the Roche Group, used the company's sequencing, bioinformatics and analytics services to sequence and compare a patient's primary lung tumor and adjacent normal tissue.

27 May 2010

Weill Cornell Medical College commences construction of 18-story, $650 million Medical Research Building

Weill Cornell Medical College today celebrated the start of construction on its new Medical Research Building, a state-of-the-art facility that will more than double the institution's existing research space. The 18-story, $650 million building is the centerpiece of Weill Cornell's $1.3 billion Discoveries that Make a Difference Campaign, the country's largest for a medical college. A total of $1 billion has been raised toward this goal in a record time of less than four years.

27 May 2010

Patients with transformed lymphoma show positive response to lenalidomide: Research

New research illustrates that some patients with transformed lymphoma showed "remarkable" response to lenalidomide, an oral drug with few side effects.

27 May 2010

Lymphoma Foundation Canada applauds Ontario government's decision to publicly fund Rituxan for CLL

Lymphoma Foundation Canada (LFC) applauds Ontario's recent decision to publicly fund Rituxan (rituximab) in combination with Fludarabine-based chemotherapy for patients with previously untreated chronic lymphocytic leukemia (CLL).

26 May 2010

CorCell reduces initial cost of storing umbilical cord blood stem cells

Cord Blood America, Inc., announced today its stem cell processing and storage subsidiary, CorCell, is launching "Afford-A-Cord," which reduces the initial cost of storing umbilical cord blood stem cells from $2075 to $495 plus medical courier service. The Afford-A-Cord program will be offered as an additional payment option to CorCell's long standing traditional payment programs.

26 May 2010

Targeted enrollment in Phase IIb trial for EpiCept NP-1 in CPN attained: EpiCept

EpiCept Corporation today announced that the targeted enrollment in a Phase IIb trial for EpiCept NP-1 in chemotherapy-induced peripheral neuropathy has been attained. The trial is being conducted by National Cancer Institute -funded Community Clinical Oncology Program.

26 May 2010

Leukemia News and Research

Further Reading

New therapy mounts double-barreled attack on leukemia, report UF researchers

Testosterone deficiency can lead to multiple disorders

ENMD-2076 demonstrates antitumor activity against murine xenograft models of CRC: Study

Asuragen obtains license to integrate BRAF V600E mutation sequence into its molecular diagnostic products

New research project to discover origin of myelodysplasia

Results from AMRI's on-going Phase I clinical study of ALB 109564(a) published online

Research team confirms gene mutation associated with serious forms of leukaemia

EpiCept provides update on post-approval commitments requested by EMA for Ceplene

Scientists identify new susceptibility genes in genome-wide association study of nasopharyngeal carcinoma

Adenosine plays major role in parlaying effects of acupuncture

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

Advocates urge Congress to reauthorize C.W. Bill Young Cell Transplantation Program and NCBI

CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial

OHSU partners with UO, Harvard to expedite research into compounds that may prevent Fanconi anemia

Genentech uses Complete Genomics' sequencing service to compare primary lung tumor, adjacent normal tissue

Weill Cornell Medical College commences construction of 18-story, $650 million Medical Research Building

Patients with transformed lymphoma show positive response to lenalidomide: Research

Lymphoma Foundation Canada applauds Ontario government's decision to publicly fund Rituxan for CLL

CorCell reduces initial cost of storing umbilical cord blood stem cells

Targeted enrollment in Phase IIb trial for EpiCept NP-1 in CPN attained: EpiCept

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News